Merck Announces Collaboration With Iktos for Generative AI Technology

Collaboration agreement enables Merck access to Iktos AI technology across three drug discovery projects Generative modelling AI technology enables rapid and cost-effective design of novel drugs Agreement is part of Merck's R&D strategy to advance drug discovery with strategic technology-focused collaborations

0
360

DARMSTADT, GermanyMarch 16, 2019 – Merck, a leading science and technology company, today announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds.

“This agreement is another illustration of how we aim to enrich our discovery engine with strategic technology-focused collaborations,” said Belén Garijo, Member of the Executive Board and CEO Healthcare, Merck. “Artificial intelligence is emerging as a pillar in the biopharmaceutical R&D model, giving us exponential opportunity to complement our existing expertise with further speed and better precision. For patients, this could mean faster access to novel treatment options.”

Iktos’ AI technology, which is based on deep generative models, helps bring speed and efficiency to the drug discovery process, by automatically designing virtual novel molecules that have desired activities for treating a given disease. This tackles one of the key challenges in drug design: rapid identification of molecules which simultaneously satisfy multiple drug-like criteria for clinical testing. The technology is already successfully established in other fields, such as image processing and automatic translation, but has only recently been applied to chemistry.

“We are thrilled that Merck is collaborating with Iktos to further accelerate its drug discovery capabilities,” commented Yann Gaston-Mathé, President and CEO of Iktos. “In a short space of time, our technology has successfully enabled huge progress and we are eager to apply the enormous possibilities it holds to help Merck with the successful design of new therapeutic options.”

Merck continues to leverage machine learning and artificial intelligence to drive transformative approaches. This follows the announcement, in December 2018, of a year-long licencing agreement with Cyclica Inc. for the use of its AI-augmented proteome screening platform, Ligand ExpressMerck also recently announced that it has been granted a U.S. Patent for a novel combination of AI and Blockchain Technology, aimed at providing a solution for the secure integration of physical products into the digital world.

For more information, visit : www.iktos.ai

LEAVE A REPLY

Please enter your comment!
Please enter your name here